apceth Biopharma GmbH
apceth's vision is to improve patients’ lives with next generation cell therapies. Our programs aim to bring transformative and curative drugs to the patients. apceth-201, are genetically modified MSCs which express Alpha-1 Antitrypsin for the treatment of GvHD, IBD, COPD and diabetes. apceth-301, are MSCs that express a potent cocktail of cytokines which locally activates the immune system to eradicate tumor cells. Apceth-301 is being developed for solid tumors. We are also a leader in GMP manufacturing of cell-based therapies offering cutting-edge expertise and capabilities. Our unique and comprehensive quality management system has allowed us to successfully obtain manufacturing authorizations for multiple cell therapy products. Our facilities are located in Munich, Germany.